Cell Rep Med. 2026 Mar 17. pii: S2666-3791(26)00071-6. [Epub ahead of print]7(3):
102654
Zhaoyi Che,
Zhihui Luo,
Dong Xiao,
Fashu Ma,
Haoxiong Zhou,
Yali Song,
Shanshan Guo,
Yuan Yuan,
Hao Wang,
Ching-Pong Mak,
Kwok-Fai So,
Jia Xiao.
Currently, no therapies are approved for alcohol-associated liver disease (ALD). Here, we identify cyclophilin D (CypD) as a critical mediator in the progression of ALD. We observe elevated expression of CypD in ALD patients and a corresponding mouse model. Hepatocyte-specific knockout of CypD mitigates hepatic mitochondrial dysfunction, steatosis, inflammation, and oxidative stress. Conversely, overexpression of CypD exacerbates hepatic mitochondrial stress. In vivo and in vitro experiments demonstrate that a CypD inhibitor, RN-0001, effectively and safely alleviates hepatic damage induced by ethanol exposure; these protective effects are absent in CypD-deficient mice. Biophysical assays indicate that RN-0001 directly binds to CypD. Additionally, absorption, distribution, metabolism, excretion, and toxicity (ADMET) tests and first-in-human phase I clinical trial identify RN-0001 as a promising translational candidate for ALD therapy. Collectively, our study highlights the pathological role of CypD in ALD and introduces a preclinical candidate for its management. This study was registered at chictr.org.cn (ChiCTR2500106709).
Keywords: alcohol-associated liver disease; cyclophilin D; mitochondrial dysfunction; preclinical candidate